MERMAID-2
A lung cancer trial that planned to start durvalumab the moment a surveillance blood test found tumour DNA, before any scan showed relapse; the registry lists it as complete with 30 participants.
Overview
MERMAID-2 was AstraZeneca's phase 3, double-blind trial of durvalumab against placebo for people with stage II to III non-small-cell lung cancer whose ctDNA became detectable during surveillance after curative treatment, the 'treat at molecular relapse' design. The registry records a start on 30 November 2020, a status of completed with 30 participants, primary completion on 31 May 2023 and study completion on 15 January 2024. Its small size is the reason the roadmap describes ctDNA-triggered escalation as unproven outside bladder cancer.
Similar pages
not linked directly; found by shared links- TrialTRACC
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag ctdna-roadmap.
- TrialBESPOKE CRC
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag ctdna-roadmap.
- TrialCIRCULATE-US
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag ctdna-roadmap.
- TrialVanguard Study (NCI Cancer Screening Research Network)
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA) and the tag ctdna-roadmap.
- PersonAsh A. Alizadeh
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- PersonSarah-Jane Dawson
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- TechnologycfDNA fragmentomics
Shares Continuous and near-continuous ctDNA monitoring, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
- IdeaCertified reference samples to benchmark every tumour-DNA blood test
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.